FDA Approves Label Changes for Both the Oral and IV Injection Forms of Reglan. The Medication is Linked to a Significant Risk of Developing Tardive Dyskinesia (TD)

Weitz & Luxenberg’s lawyers are meeting with patients who developed tardive dyskinesia (TD) after being prescribed the medication Reglan. In June 2009, the U.S. Food and Drug Administration (FDA)approved the following label changes for both the oral tablets and IV infusion versions of the drug.

If you or someone in your family suffered a Reglan injury, please complete the form on this page for important information about legal rights.

Reglan (metoclopramide) tablets, ODT (Orally Disintegrating Tablets), and injection Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Boxed Warning: Tardive Dyskinesia

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

Warnings: Tardive Dyskinesia

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD. Although the risk of developing TD in the general population may be increased among the elderly.

Metoclopramide should be discontinued in patients who develop signs or symptoms or side effects associated with TD.

Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process.

Get Help from a Weitz & Luxenberg Lawyer
If you or a family member has been diagnosed with tardive dyskinesia after taking Reglan, you may be able to seek compensation from companies that market the drug.

Please complete the form on this page for a confidential and free review of your possible Reglan lawsuit. A Weitz & Luxenberg representative will contact you as soon as possible.

Click To Talk To Us Online

FDA Information

Reglan drug linked to tardive dyskinesia | Weitz & Luxenberg attorneys
Free lawsuit review is available for those who developed tardive dyskinesia after taking the gastrointestinal drug Reglan.

Box Warning

Risks linked to the drug Reglan (Metoclopramide) | Weitz & Luxenberg
Those who developed tardive dyskinesia after taking Reglan (Metoclopramide) can get a freee review of their potential case from our lawyers.

Name

Phone

strictly confidential

Your Question

Name
Email address
City/State
Date you began taking Reglan
Date you quit taking Reglan
Were you diagnosed with tardive dyskinesia?
Describe your symptoms
Phone number (optional)